Health Care & Life Sciences » Biotechnology | Asterias Biotherapeutics Inc.

Asterias Biotherapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
-
1,223.70
3,582.00
6,954.00
4,042.00
Cost of Goods Sold (COGS) incl. D&A
948.60
5,414.40
3,518.00
3,990.00
3,961.00
Gross Income
948.60
4,190.70
64.00
2,964.00
81.00
SG&A Expense
7,254.10
13,270.50
21,972.00
34,527.00
30,032.00
EBIT
8,202.70
17,461.20
-
31,563.00
29,951.00
Unusual Expense
17,458.80
-
-
5,668.00
2,608.00
Non Operating Income/Expense
1.00
1.60
6.00
37.00
564.00
Interest Expense
-
10.00
341.00
546.00
465.00
Pretax Income
25,660.40
17,472.80
22,255.00
37,814.00
28,372.00
Income Tax
3,280.70
7,375.60
7,252.00
2,325.00
-
Consolidated Net Income
22,379.70
10,097.20
15,003.00
35,489.00
28,372.00
Net Income
22,379.70
10,097.20
15,003.00
35,489.00
28,372.00
Net Income After Extraordinaries
22,379.70
10,097.20
15,003.00
35,489.00
28,372.00
Net Income Available to Common
22,379.70
10,097.20
15,003.00
35,489.00
28,372.00
EPS (Basic)
3.42
0.33
0.42
0.83
0.56
Basic Shares Outstanding
6,537.80
30,720.30
35,443.00
42,934.00
50,271.00
EPS (Diluted)
3.42
0.33
0.42
0.83
0.56
Diluted Shares Outstanding
6,537.80
30,720.30
35,443.00
42,934.00
50,271.00
EBITDA
7,254.10
12,141.40
18,658.00
27,701.00
26,155.00

About Asterias Biotherapeutics

View Profile
Address
6300 Dumbarton Circle
Fremont California 94555
United States
Employees -
Website http://www.asteriasbiotherapeutics.com
Updated 09/14/2018
Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. The company is also focused on developing therapies to treat conditions with unmet medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.